About: Antibody Derived Peptides for Detection of Ebola Virus Glycoprotein

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Antibody Derived Peptides for Detection of Ebola Virus Glycoprotein Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Antibody Derived Peptides for Detection of Ebola Virus Glycoprotein
Creator	Zhang, Yu González-González, Everardo Khademhosseini, Ali Pérez-Chavarría, Roberto Moisés Alvarez, Mario Carlos González-Vázquez, Juan Dokmeci, Mehmet López-Pacheco, Mario Rodríguez-Martínez, Luis Ponce-Ponce De León, Alejandro Roberto Marquez-Ipiña, Trujillo-De Santiago, Grissel
Source	PMC
abstract	BACKGROUND: Current Ebola virus (EBOV) detection methods are costly and impractical for epidemic scenarios. Different immune-based assays have been reported for the detection and quantification of Ebola virus (EBOV) proteins. In particular, several monoclonal antibodies (mAbs) have been described that bind the capsid glycoprotein (GP) of EBOV GP. However, the currently available platforms for the design and production of full-length mAbs are cumbersome and costly. The use of antibody fragments, rather than full-length antibodies, might represent a cost-effective alternative for the development of diagnostic and possibly even therapeutic alternatives for EBOV. METHODS/PRINCIPAL FINDINGS: We report the design and expression of three recombinant anti-GP mAb fragments in Escherichia coli cultures. These fragments contained the heavy and light variable portions of the three well-studied anti-GP full-length mAbs 13C6, 13F6, and KZ52, and are consequently named scFv-13C6, scFv-13F6, and Fab-KZ52, respectively. All three fragments exhibited specific anti-GP binding activity in ELISA experiments comparable to that of full-length anti-GP antibodies (i.e., the same order of magnitude) and they are easily and economically produced in bacterial cultures. CONCLUSION/SIGNIFICANCE: Antibody fragments might represent a useful, effective, and low cost alternative to full-length antibodies in Ebola related capture and diagnostics applications.
has issue date	2015-10-21(xsd:dateTime)
bibo:doi	10.1371/journal.pone.0135859
bibo:pmid	26489048
has license	cc-by
sha1sum (hex)	693b013cbc9a762c6116b82a671e2eb24b1731b6
schema:url	https://doi.org/10.1371/journal.pone.0135859
resource representing a document's title	Antibody Derived Peptides for Detection of Ebola Virus Glycoprotein
has PubMed Central identifier	PMC4619498
has PubMed identifier	26489048
schema:publication	PLoS One
resource representing a document's body	covid:693b013cbc9a762c6116b82a671e2eb24b1731b6#body_text
is schema:about of	named entity 'BASED' named entity 'HAVE' named entity 'LENGTH' named entity 'FRAGMENTS' named entity 'POSSIBLY' named entity 'THERAPEUTIC' named entity 'PRODUCTION' named entity 'CURRENTLY' named entity 'USE OF' named entity 'SCENARIOS' named entity 'DIAGNOSTIC' named entity 'EBOLA VIRUS' named entity 'DEVELOPMENT' named entity 'REPORTED' named entity 'EFFECTIVE' named entity 'RATHER' named entity 'MONOCLONAL ANTIBODIES' named entity 'proteins' named entity 'mAbs' named entity 'production' named entity 'Detection' covid:arg/693b013cbc9a762c6116b82a671e2eb24b1731b6 named entity 'REPRESENT' named entity 'DESCRIBED' named entity 'BIND' named entity 'ANTIBODY' named entity 'EPIDEMIC' named entity 'DETECTION' named entity 'IMMUNE' named entity 'ANTIBODY' named entity 'EBOLA VIRUS' named entity 'DETECTION' named entity 'CAPSID' named entity 'EBOV GP' named entity 'CURRENT' named entity 'DESIGN' named entity 'AVAILABLE' named entity 'COST' named entity 'PROTEINS' named entity 'ALTERNATIVE' named entity 'GLYCOPROTEIN' named entity 'DERIVED' named entity 'PEPTIDES' named entity 'GLYCOPROTEIN' named entity 'PARTICULAR' named entity 'DETECTION METHODS' named entity 'QUANTIFICATION' named entity 'ANTIBODIES' named entity 'DIFFERENT' named entity 'glycoprotein' named entity 'Glycoprotein' named entity 'EBOV' named entity 'EBOV' named entity 'mAbs' named entity 'epidemic' named entity 'mAbs' named entity 'Ebola' named entity 'virus' named entity 'interact' named entity 'isopropyl thiogalactoside' named entity 'scFv' named entity 'PBS' named entity 'antibody' named entity 'binding affinity' named entity 'peroxidase' named entity 'Infliximab' named entity 'antibody' named entity 'binding affinities' named entity 'supernatant' named entity 'mAb'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software